We herein report a novel compound heterozygous mutation of the acid α-glucosidase (GAA) gene in a 23-year-old man with adult-onset Pompe disease. The patient was admitted for respiratory failure and a highly elevated serum level of creatine kinase (CK). His muscle pathology did not show typical vacuolated fibers; however, globular inclusion bodies with acid phosphatase (ACP) activity was observed. A molecular genetic analysis of the GAA gene revealed a novel compound heterozygous mutation, c.1544 T>A (M515K), combined with a previously reported mutation, c.1309 C>T (R437C). The presence of ACP-positive globular inclusion bodies is a useful diagnostic marker for adult-onset Pompe disease, even when typical vacuolated fibers are absent.
Introduction
Pompe disease (glycogen storage disease type II, GSD II) is an autosomal-recessive lysosomal storage disorder caused by a deficiency of acid α-glucosidase (GAA). Based on the age of onset and clinical severity, the disease is classified into infantile, childhood-onset and adult-onset forms (1) (2) (3) (4) (5) (6) . The GAA gene is located on chromosome 17q25.2-q25. 3 . Mutations in this gene vary widely, including missense, nonsense, large and small insertions and deletions, and frameshift mutations. In general, a good correlation between the nature of the mutation, the degree of residual enzyme activity and the severity of the clinical presentation is observed (7) (8) (9) . Most of the infantile and childhood-onset forms exhibit a disease-specific skeletal muscle pathology including fibers occupied by huge vacuoles that contain basophilic amorphous material; however, diagnosing the adultonset form is challenging due to clinical similarities with muscular dystrophy and the paucity of typical vacuolated myofibers. We herein report a novel mutation of the GAA gene in a patient with adult-onset Pompe disease lacking a disease-specific pathology.
Case Report
A 23-year-old man was admitted to our hospital due to respiratory insufficiency. His serum levels of creatine kinase (CK) and transaminases were found to be elevated at age 18; however, he had not noticed weakness of his extremities. He had no particular medical or family history. On admission, a physical examination revealed a thin man measuring, . The functional vital capacity (FVC) was markedly reduced to 26.1% of the normal predicted value for the patient's age. Electrocardiography (ECG) revealed incomplete right bundle branch block, while echocardiography demonstrated pulmonary hypertension. A computed tomography (CT) scan disclosed skeletal muscle atrophy in the extremities (Figure A, arrowheads) . Brain magnetic resonance imaging (MRI) showed no abnormalities. Needle electromyography (EMG) of the upper and lower extremities demonstrated myogenic conversion with a low amplitude motor unit potential and myotonic-like repetitive discharges. A muscle biopsy of the left biceps brachii revealed fibers with nonspecific vacuoles in addition to a mild variation in fiber size ( Figure B, arrow) . No necrotic or regenerating fibers were observed. On periodic acid Schiff (PAS) staining, the glycogen level was found to have increased in scattered fibers. Inclusion bodies were stained only faintly on acid phosphatase [ACP ( Figure C) ]. A biochemical analysis of the muscle tissue confirmed the diagnosis of Pompe disease, as the α-glucosidase activity in leukocytes was found to be 11.9 nmol/mg protein/hr (control range, 13.1-46.3 nmol/mg protein/hr) and the acid α-glucosidase activity in the muscle was found to be 2.0 nmoles 4 MU/mg/30 min (control range, 14.6±4.8 nmoles 4 MU/mg/30 min).
DNA was extracted from peripheral blood lymphocytes after obtaining the patient's informed consent. Each exon and flanking sequence of the GAA gene were amplified via polymerase chain reaction (PCR), and the amplified fragments were directly sequenced. We identified a compound heterozygous mutation, c.1309 C>T (R437C), in exon 8 and a novel compound heterozygous mutation, c.1544 T>A (M515K), in exon 10 ( Figure D, E) . The patient's father was heterozygous for c.1309 C>T (R437C) in exon 8 (Figure F, G) . The patient's mother was heterozygous for c.1544 T>A (M515K) in exon 10 ( Figure H, I ).
Non invasive positive pressure ventilation (NPPV) was performed only during the night due to the patient's respiratory failure. He received an intravenous infusion of recombinant human acid α-glucosidase (rhGAA; 20 mg/kg body weight) every two weeks. After one year of rhGAA treatment, his muscular strength remained 4/5 on the MRC scale. The FVC remained low at 27.3% of the predicted value for his age. The serum levels of CK and hepatic enzymes decreased. Thereafter, the patient's clinical manifestations did not worsen.
Discussion
We herein report a novel compound heterozygous mutation of the GAA gene in the present patient. Currently, 455 variants in the GAA gene have been described, 364 of which are considered to be disease-causing mutations (www. pompecenter.nl). The mutations are randomly spread throughout the entire gene and are typically discrete. The primary effect of the residual enzyme activity on the clinical course of Pompe disease can be confirmed (10) . The residual activity observed in adult-onset Pompe disease patients correlates with a later age of onset and slower disease progression. As reported in previous studies, the most common c.-32-13 T> G mutation is associated with a milder course, although there is broad variability in the decline in the locomotive and respiratory functions (11) . Our patient exhibited slowly progressive proximal muscular weakness and respiratory failure because the enzyme activity was slightly reduced. The residual activity of this enzyme is primarily determined by the severity of the pathogenic mutations in both GAA alleles and is likely controlled by unknown modifying factors.
Respiratory failure as an early symptom of neuromuscular disease is rare; however, it has been previously described, not only in patients with Pompe disease, but also those with motor neuron disease, myasthenia gravis and WerdnigHoffmann disease (12) . Diagnosing adult-onset Pompe disease is sometimes challenging due to its clinical similarities with muscular dystrophy and the paucity of disease-specific vacuolated fibers in the skeletal muscle pathology. Importantly, 20% of patients with non-classic Pompe disease have a normal muscle glycogen content. Likewise, not all muscle biopsies disclose morphologic abnormalities. In the literature this is most often reported in patients presenting with symptoms after 18 years of age (13) . Our patient did not exhibit typical vacuolated fibers, although he did demonstrate unique globular inclusion bodies with ACP activity. The presence of globular inclusions is suggestive of cytoplasmic bodies, which are nonspecific findings reflecting degeneration of the Z-disk in patients with various neuromuscular diseases. Although it remains unclear how ACP-positive globular inclusions are formed, the absence of glycogen in the globular inclusion bodies suggests that they differ from the areas of glycogen accumulation observed in lysosomes (14) . The presence of ACP-positive globular inclusion bodies is a hallmark of Pompe disease and a useful diagnostic marker for adult-onset Pompe disease in patients lacking typical vacuolated fibers (14) . Since enzyme replacement therapy is effective in adult-onset patients, making an early diagnosis is necessary in order to obtain a better prognosis.
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